Rigel Pharmaceuticals | Actif À Court Terme





Actif À Court Terme Changement Date
Agenus USD 133.95M 120.61M 2025-09
Amgen USD 29.06B 1.17B 2025-12
Anika Therapeutics USD 101.59M 2.27M 2025-09
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Celldex Therapeutics USD 534.66M 69.68M 2025-12
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 229.4M 18.48M 2025-09
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Karyopharm Therapeutics USD 89.75M 8.12M 2025-09
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
MacroGenics USD 232.09M 27.15M 2025-09
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Veracyte USD 488.38M 39.15M 2025-12


Rigel Pharmaceuticals Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.